blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2295056

EP2295056 - Use of SNS-595 for treating leukemia [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  11.11.2016
Database last updated on 21.03.2026
Most recent event   Tooltip13.07.2018Lapse of the patent in a contracting state
New state(s): TR		published on 15.08.2018  [2018/33]
Applicant(s)For all designated states
Sunesis Pharmaceuticals, Inc.
395 Oyster Point Blvd., Suite 400
South San Francisco, CA 94080 / US
For all designated states
Sumitomo Dainippon Pharma Co., Ltd.
6-8, Dosho-machi 2-chome
Chuo-ku
Osaka-shi
Osaka 541-8524 / JP
[2015/12]
Former [2015/11]For all designated states
Sunesis Pharmaceuticals, Inc.
395 Oyster Point Blvd., Suite 400
South San Francisco, CA 94080 / US
For all designated states
Dainippon Sumitomo Pharma Co., Ltd.
6-8, Dosho-machi 2-chome Chuo-ku Osaka-shi
Osaka 541-8524 / JP
Former [2011/15]For all designated states
Sunesis Pharmaceuticals, Inc.
395 Oyster Point Blvd., Suite 400
South San Francisco, CA 94080 / US
For all designated states
Dainippon Sumitomo Pharma Co., Ltd.
6-8, Dosho-machi 2-chome, Chuo-ku Osaka-shi
Osaka, 541-8524 / JP
Former [2011/11]For all designated states
Sunesis Pharmaceuticals, Inc.
395 Oyster Point Blvd., Suite 400
South San Francisco, CA 94080 / US
For all designated states
Dainippon Sumitomo Pharma Co., Ltd.
5-51 Ebie 1-chome Fukushima-ku Osaka-shi
Osaka 553-0001 / JP
Inventor(s)01 / Adelman, Daniel, C.
23 Woodleaf Avenue
Redwood City, CA 94061 / US
02 / Silverman, Jeffrey A.
1416 Columbus Avenue
Burlingame, CA 94010 / US
03 / MASARU, Higaki
c/o Sumitomo Dainippon Pharma Co., Ltd.
6-8, Dosho-machi 2-chome
Chuo-ku
Osaka-shi, Osaka 541-8524 / JP
04 / SATOSHI, Nakao
c/o Sumitomo Dainippon Pharma Co., Ltd.
6-8, Dosho-machi 2-chome
Chuo-ku
Osaka-shi
Osaka-shi, Osaka 541-8524 / JP
 [2016/04]
Former [2015/03]01 / Adelman, Daniel, C.
23 Woodleaf Avenue
Redwood City, CA 94061 / US
02 / Silverman, Jeffrey A.
1416 Columbus Avenue
Burlingame, CA 94010 / US
03 / MASARU, Higaki
5-51, Ebie 1-chome,
Fukushima-ku
Osaka-shi, Osaka 553-0001 / JP
04 / SATOSHI, Nakao
5-51, Ebie 1-chome,
Fukushima-ku
Osaka-shi, Osaka 553-0001 / JP
Former [2011/19]01 / Adelman, Daniel, C.
23 Woodleaf Avenue
Redwood City, CA 94061 / US
02 / Silverman, Jeffrey A.
1416 Columbus Avenue
Burlingame, CA 94010 / US
Representative(s)Savic, Bojan, et al
Jones Day
Rechtsanwälte Attorneys-at-Law Patentanwälte
Prinzregentenstraße 11
80538 München / DE
[2013/52]
Former [2011/11]Ritter, Thomas Kurt, et al
Jones Day Prinzregentenstraße 11
80538 München / DE
Application number, filing date10177951.014.03.2005
[2011/11]
Priority number, dateUS20040553578P15.03.2004         Original published format: US 553578 P
[2011/11]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2295056
Date:16.03.2011
Language:EN
[2011/11]
Type: B1 Patent specification 
No.:EP2295056
Date:06.01.2016
Language:EN
[2016/01]
Type: B9 Corrected patent specification 
No.:EP2295056
Date:28.09.2016
[2016/39]
Search report(s)(Supplementary) European search report - dispatched on:EP26.01.2011
ClassificationIPC:A61K31/44, A61P35/00, A61P35/02, A61K38/18, A61K9/00, A61K31/4745, A61K31/555, A61K31/4375, A61K31/7068, A61K41/00, A61K45/06, A61K47/12, C07D471/04
[2015/04]
CPC:
A61K9/0019 (EP,US); A61K31/44 (EP,KR,NO,US); A61K31/4375 (EP,CN,NO,US);
A61K31/282 (EP,US); A61K31/337 (EP,US); A61K31/395 (EP,US);
A61K31/407 (EP,US); A61K31/4745 (EP,US); A61K31/513 (EP,US);
A61K31/519 (EP,US); A61K31/52 (EP,US); A61K31/555 (EP,US);
A61K31/585 (EP,US); A61K31/704 (EP,US); A61K31/7048 (EP,US);
A61K31/7068 (EP,US); A61K38/15 (EP,US); A61K38/1816 (EP,US);
A61K41/00 (EP,US); A61K45/06 (EP,US); A61K47/12 (US);
A61P1/08 (EP); A61P13/08 (EP); A61P35/00 (EP);
A61P35/02 (EP); A61P43/00 (EP); A61P7/06 (EP);
C07D471/04 (EP,US); F24S10/70 (EP,US); F24S50/40 (EP,US);
F24S80/60 (EP,US); H02S40/38 (EP,US); H02S40/44 (US);
H10F77/488 (EP,US); H10F77/63 (US); Y02E10/40 (US);
Y02E10/44 (EP); Y02E10/52 (EP,US); Y02E10/60 (EP);
Y02E70/30 (EP) (-)
C-Set:
A61K31/44, A61K2300/00 (EP,US);
A61K31/4745, A61K2300/00 (US,EP);
A61K31/555, A61K2300/00 (US,EP);
A61K41/00, A61K2300/00 (US,EP)
Former IPC [2011/11]A61K31/44, A61P35/00, A61P35/02, A61K38/18, A61K9/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/01]
Former [2011/11]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:Verwendung von SNS-595 zur Behandlung von Leukämie[2011/11]
English:Use of SNS-595 for treating leukemia[2011/11]
French:Utilisation du SNS-595 pour le traitement de la leucémie[2011/11]
Examination procedure14.09.2011Amendment by applicant (claims and/or description)
14.09.2011Examination requested  [2011/43]
06.03.2012Despatch of a communication from the examining division (Time limit: M06)
07.08.2012Reply to a communication from the examining division
23.07.2013Despatch of a communication from the examining division (Time limit: M06)
03.02.2014Reply to a communication from the examining division
09.12.2014Date of oral proceedings
12.01.2015Minutes of oral proceedings despatched
11.02.2015Communication of intention to grant the patent
26.05.2015Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
24.06.2015Communication of intention to grant the patent
21.10.2015Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
21.10.2015Fee for grant paid
21.10.2015Fee for publishing/printing paid
05.11.2015Information about intention to grant a patent
05.11.2015Receipt of the translation of the claim(s)
09.03.2016Request for correction of the decision to grant filed
Parent application(s)   TooltipEP05731600.2  / EP1725233
Divisional application(s)EP15202939.3  / EP3053579
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20050731600) is  04.08.2009
Opposition(s)07.10.2016No opposition filed within time limit [2016/50]
Fees paidRenewal fee
21.09.2010Renewal fee patent year 03
21.09.2010Renewal fee patent year 04
21.09.2010Renewal fee patent year 05
21.09.2010Renewal fee patent year 06
15.03.2011Renewal fee patent year 07
14.03.2012Renewal fee patent year 08
11.03.2013Renewal fee patent year 09
12.03.2014Renewal fee patent year 10
10.03.2015Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY06.01.2016
EE06.01.2016
FI06.01.2016
LT06.01.2016
RO06.01.2016
SI06.01.2016
SK06.01.2016
TR06.01.2016
BG06.04.2016
IS06.05.2016
[2018/33]
Former [2018/28]CY06.01.2016
EE06.01.2016
FI06.01.2016
LT06.01.2016
RO06.01.2016
SI06.01.2016
SK06.01.2016
BG06.04.2016
IS06.05.2016
Former [2017/15]EE06.01.2016
FI06.01.2016
LT06.01.2016
RO06.01.2016
SI06.01.2016
SK06.01.2016
BG06.04.2016
IS06.05.2016
Former [2016/50]EE06.01.2016
FI06.01.2016
LT06.01.2016
RO06.01.2016
SK06.01.2016
IS06.05.2016
Former [2016/49]EE06.01.2016
FI06.01.2016
LT06.01.2016
IS06.05.2016
Former [2016/38]FI06.01.2016
LT06.01.2016
IS06.05.2016
Former [2016/36]FI06.01.2016
LT06.01.2016
Former [2016/35]FI06.01.2016
Documents cited:Search[I] US5817669  (TOMITA KYOJI et al.) [I] 1-13 * column 45; example D1; claim 15; tables 1,2; compound 1 *
 [Y] US2003216316  (HARAN-GHERA NECHAMA et al.) [Y] 1-13 * abstract *
 [Y] US5078996  (CONLON III PAUL J et al.) [Y] 1-13 * abstract *
 [Y] WO0174395  (BAXTER INT et al.) [Y] 1-13 * the whole document *
 [I]   TSUZUKI ET AL: "Synthesis and Structure-Activity Relationships of Novel 7-Substituted 1,4-Dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic Acids as Antitumor Agents. Part 2", 1 January 2004, JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON., US, PAGE(S) 2097 - 2109, ISSN: 0022-2623, XP002352356 [I] 1-13 * the whole document *

DOI:   http://dx.doi.org/10.1021/jm0304966
 [Y]   HERMAN T ET AL: "Nabilone: a potent antiemetic cannabinol with minimal euphoria", MEDLINE,, 1 December 1977 (1977-12-01), XP003022271 [Y] 1-4 * abstract *
Examination  DIETER HAFNER ET AL: "Pharmakokinetik in der Apothekenpraxis", PHARMAZEUTISCHE WISSENSCHAFT, 1 January 2004 (2004-01-01), pages 264 - 269, XP055158695, Retrieved from the Internet [retrieved on 20141215]
   VORTRAG: "Prinzipielle pharmakokinetische berlegungen des Notarztes", 31 May 2003 (2003-05-31), XP055158735, Retrieved from the Internet [retrieved on 20141215] [I] 1-13 * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.